Published in Disease Risk Factor Week, November 1st, 2009
"Consolidation therapy comprised three courses of anthracycline monochemotherapy (LPA96), with all-trans retinoic acid and reinforced doses of idarubicin in patients with an intermediate or high...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Disease Risk Factor Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.